A2 Refereed review article in a scientific journal

A systematic review and meta-analysis of lung cancer risk prediction models




AuthorsKhalife, Ghida; Nilsson, Matilda; Peltola, Lotta; Waris, Juho; Jekunen, Antti; Leskelä, Riikka-Leena; Andersén, Heidi; Nuutinen, Mikko; Heikkilä, Eija; Nurmi-Rantala, Susanna; Torkki, Paulus

PublisherInforma UK Limited

Publication year2025

JournalActa Oncologica

Journal name in sourceActa Oncologica

Volume64

First page 661

Last page671

eISSN1651-226X

DOIhttps://doi.org/10.2340/1651-226X.2025.42529

Web address https://doi.org/10.2340/1651-226x.2025.42529

Self-archived copy’s web addresshttps://research.utu.fi/converis/portal/detail/Publication/498636977


Abstract

Background: Lung cancer (LC) remains the leading cause of cancer-related mortality worldwide. Early detection through targeted screening significantly improves patient outcomes. However, identifying high-risk individuals remains a critical challenge.

Purpose: This systematic review evaluates externally validated LC risk prediction models to assess their performance and potential applicability in screening strategies.

Methods: Of the 11,805 initial studies, 66 met inclusion criteria and 38 published mainly between 2020 and 2024 were included in the final analysis. Model methodologies, validation approaches, and performance metrics were extracted and compared.

Results: The review identified 18 models utilising conventional machine learning, six employing neural networks, and 14 comparing different predictive frameworks. The Prostate Lung Colorectal and Ovarian Cancer Screening Trial (PLCOm2012) demonstrated superior sensitivity across diverse populations, while newer models, such as Optimized Early Warning model for Lung cancer risk (OWL) and CanPredict, showed promising results. However, differences in population demographics and healthcare systems may limit the generalisability of these models.

Interpretation: While LC risk prediction models have advanced, their applicability to specific healthcare systems, such as Finland's, requires further adaptation and validation. Future research should focus on optimising these models for local contexts to improve clinical impact and cost-effectiveness in targeted screening programmes.

Systematic review registration: PROSPERO CRD42022321391.


Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Funding information in the publication
This work was supported by AstraZeneca Finland and MSD Finland. Open access funded by Helsinki University Library.


Last updated on 2025-14-08 at 10:41